|
|
Volumn 3, Issue 1, 2002, Pages 14-16
|
|
Fast tracking drugs to patients. Drug approval agencies are frequently criticised for either being too slow or too fast
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;
ANTIBIOTIC AGENT;
ANTINEOPLASTIC AGENT;
BACTERIUM ANTIBODY;
CIPROFLOXACIN;
IMATINIB;
MONOCLONAL ANTIBODY;
SMALLPOX VACCINE;
ANTHRAX;
BIOLOGICAL WARFARE;
CLINICAL STUDY;
CONTROLLED STUDY;
DRUG APPROVAL;
DRUG COST;
DRUG INDUSTRY;
DRUG MARKETING;
DRUG SCREENING;
DRUG SYNTHESIS;
HUMAN;
IMMUNITY;
INFECTION RESISTANCE;
MEDICAL ETHICS;
NOTE;
PRIORITY JOURNAL;
PROVOCATION TEST;
SIDE EFFECT;
VACCINE PRODUCTION;
ANTHRAX;
ANTI-INFECTIVE AGENTS;
BIOTERRORISM;
CIPROFLOXACIN;
DRUG APPROVAL;
EUROPE;
TIME FACTORS;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
ANTHRAX;
BACTERIA (MICROORGANISMS);
HUMAN IMMUNODEFICIENCY VIRUS;
VARIOLA VIRUS;
|
|
EID: 0036169488
PISSN: 1469221X
EISSN: None
Source Type: Journal
DOI: 10.1093/embo-reports/kvf020 Document Type: Note |
|
Times cited : (7)
|
|
References (0)
|